157 related articles for article (PubMed ID: 34552943)
1. Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France.
Cottin V; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Jouneau S; Hachulla E; Chollet J; Nasser M
Front Med (Lausanne); 2021; 8():699532. PubMed ID: 34552943
[No Abstract] [Full Text] [Related]
2. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
[TBL] [Abstract][Full Text] [Related]
4. The clinical and economic burden of systemic sclerosis related interstitial lung disease.
Morrisroe K; Stevens W; Sahhar J; Ngian GS; Ferdowsi N; Hansen D; Patel S; Hill CL; Roddy J; Walker J; Proudman S; Nikpour M
Rheumatology (Oxford); 2020 Aug; 59(8):1878-1888. PubMed ID: 31740961
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
[TBL] [Abstract][Full Text] [Related]
6. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study.
Knarborg M; Løkke A; Hilberg O; Ibsen R; Sikjaer MG
Respirology; 2022 May; 27(5):341-349. PubMed ID: 35224821
[TBL] [Abstract][Full Text] [Related]
8. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
[TBL] [Abstract][Full Text] [Related]
9. Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years.
Pope JE; Quansah K; Hassan S; Seung SJ; Flavin J; Kolb M
J Rheumatol; 2021 Sep; 48(9):1427-1434. PubMed ID: 33795325
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease.
Bergamasco A; Hartmann N; Wallace L; Verpillat P
Clin Epidemiol; 2019; 11():257-273. PubMed ID: 31114386
[No Abstract] [Full Text] [Related]
11. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
[TBL] [Abstract][Full Text] [Related]
12. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
[TBL] [Abstract][Full Text] [Related]
13. Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study.
Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
Chron Respir Dis; 2022; 19():14799731221125559. PubMed ID: 36123773
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease.
Gleason JB; Patel KB; Hernandez F; Hadeh A; Highland KB; Rahaghi F; Mehta JP
Lung; 2017 Aug; 195(4):403-409. PubMed ID: 28456874
[TBL] [Abstract][Full Text] [Related]
15. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
Young A; Vummidi D; Visovatti S; Homer K; Wilhalme H; White ES; Flaherty K; McLaughlin V; Khanna D
Arthritis Rheumatol; 2019 Aug; 71(8):1339-1349. PubMed ID: 30762947
[TBL] [Abstract][Full Text] [Related]
17. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
18. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data.
Fagnani F; Laurendeau C; de Zelicourt M; Marshall J
Epilepsia Open; 2022 Dec; 7(4):633-644. PubMed ID: 36029029
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
